Trying to learn how to translate from the human translation examples.
From professional translators, enterprises, web pages and freely available translation repositories.
maligniteettiriskiä ei voida sulkea pois lapsilla ja nuorilla, jotka saavat tnf-antagonistihoitoa.
a risk for the development of malignancies in children and adolescents treated with tnf-antagonists cannot be excluded.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
tämänhetkisten tietojen perusteella lymfoomien tai muiden maligniteettien kehittymisriskiä ei voida sulkea pois tnf-antagonistihoitoa saavien potilaiden kohdalla.
with the current knowledge, a possible risk for the development of lymphomas or other malignancies in patients treated with a tnf-antagonist cannot be excluded.
Last Update: 2017-04-26
Usage Frequency: 6
Quality:
esiintyvyys oli kuitenkin harvinaista, ja plaseboa saaneiden potilaiden seuranta-aika lyhyempi kuin tnf antagonistihoitoa saaneilla potilailla.
however, the occurrence was rare, and the follow-up period of placebo patients was shorter than for patients receiving tnf-antagonist therapy.
Last Update: 2008-03-04
Usage Frequency: 8
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
esiintyvyys oli kuitenkin harvinaista, ja plaseboa saaneiden potilaiden seuranta-aika lyhyempi kuin tnf – antagonistihoitoa saaneilla potilailla.
however, the occurrence was rare, and the follow-up period of placebo patients was shorter than for patients receiving tnf-antagonist therapy.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
esiintyvyys oli kuitenkin harvinaista, ja plaseboa saaneiden potilaiden seuranta-aika oli lyhyempi kuin tnf- antagonistihoitoa saaneilla potilailla.
however, the occurrence was rare, and the follow-up period of placebo patients was shorter than for patients receiving tnf-antagonist therapy.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
nti joilla on hyvin aktiivinen, pitkään kestänyt tulehduksellinen tauti, mikä vaikeuttaa riskin arviointia. tämänhetkisten tietojen perusteella lymfoomien tai muiden maligniteettien kehittymisriskiä ei voida sulkea pois tnf-antagonistihoitoa saavien potilaiden kohdalla.
au disease, which complicates the risk estimation.with the current knowledge, a possible risk for the development of lymphomas or other malignancies in patients treated with a tnf-antagonist cannot be excluded.
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
lisäksi lymfooman taustariski on suurentunut nivelreumapotilailla, joilla on hyvin aktiivinen, pitkään kestänyt tulehduksellinen tauti, mikä vaikeuttaa riskin arviointia. tämänhetkisten tietojen perusteella lymfoomien tai muiden maligniteettien kehittymisriskiä ei voida sulkea pois tnf-antagonistihoitoa saavien potilaiden kohdalla.
furthermore, there is an increased background lymphoma risk in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates the risk estimation.
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.